Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.75 |
| ▸ | MRE11 | P49959 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darbufelone SCHEMBL452951 | 1.00 | PTGS2 (0.75) | PTGS2PTGS1MRE11CYP1A2CYP2C9 | |
| Darbufelone SCHEMBL452950 | 1.00 | PTGS2 (0.75) | PTGS2PTGS1MRE11CYP1A2CYP2C9 | |
| Darbufelone SCHEMBL2683037 | 0.94 | PTGS2 (0.67) | PTGS2PTGS1MRE11CYP1A2CYP2C9 | |
| SCHEMBL8962138 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1GAAALOX5 | |
| SCHEMBL3667216 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1GAAALOX5 | |
| SCHEMBL3667218 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1GAAALOX5 | |
| SCHEMBL8618544 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1GAAMEN1KMT2A | |
| SCHEMBL7768284 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1GAAMEN1KMT2A | |
| SCHEMBL8309757 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1GAAMEN1KMT2A | |
| SCHEMBL8492533 | 0.82 | PTGS2 (0.51) | PTGS2PTGS1MRE11CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0914122-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1999-05-12 | — | — | EP | claimed |
| WO-1998002160-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1998-01-22 | — | — | WO | claimed |
| EP-0449216-B1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER LAMBERT CO (US) | 1996-02-07 | — | — | EP | claimed |
| US-5143928-A | Inhibitors of cyclooxygenase and lipoxygenase | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | claimed |
| EP-0449216-A1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | claimed |
| EP-0914122-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998002160-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |